Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed a Form 8-K on April 15, 2026, reporting the appointment of a new executive officer. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Charles Q. Morris, M.D., as Chief Medical Officer, effective April 20, 2026. Dr. Morris joins from Lava Therapeutics N.V., where he served as Chief Medical Officer until its acquisition by XOMA Royalty in October 2025.
Management Commentary and Compensation Terms
The Board approved an employment agreement with Dr. Morris containing the following terms:
- Base Salary: $535,000 annually.
- Bonus: Discretionary annual bonus up to 40% of the base salary.
- Equity: Option to purchase 450,000 shares of common stock. Vesting begins one year after the appointment date (25%), followed by monthly vesting of 1/48th of the remaining shares.
- Severance (Standard): In the event of termination without "Cause" or resignation for "Good Reason," Dr. Morris is entitled to nine months of base salary and healthcare coverage.
- Severance (Change in Control): If termination occurs within 12 months of a Change in Control, benefits include 12 months of base salary, 100% of the target bonus, 12 months of healthcare, and 100% accelerated vesting of equity awards.
Investor Verification Checklist
- Verify the full text of the Employment Agreement when filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2026.
- Confirm the vesting schedule and exercise price of the 450,000 stock options granted.
- Monitor the company's cash burn rate to assess the impact of the new executive compensation on liquidity.
- Review the company's pipeline status to understand the strategic rationale for appointing a Chief Medical Officer with oncology experience.